CRISPR Market
CRISPR Market by Offering (Products [Kits, Enzymes, Libraries], Services [gRNA Synthesis, Cell Line Development, Screening, Validation]), Application (Drug Discovery, Development, Agriculture), End User, Competition, Region - Global Forecast to 2031
CRISPR MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global CRISPR market is projected to grow from USD 3.48 billion in 2026 to USD 6.12 billion by 2031, at a CAGR of 12.0% during the forecast period. The market was valued at USD 3.19 billion in 2025. The growth of the CRISPR market is driven by the increasing adoption of gene editing technologies, along with rising demand for CRISPR-based therapeutics, drug discovery, functional genomics, and high-throughput screening. Expanding use of CRISPR in target identification, cell line development, disease modeling, and agricultural applications is accelerating the adoption of CRISPR products and services across pharmaceutical, biotechnology, and research settings. Additionally, continued advances in CRISPR-Cas systems, gRNA design and optimization, and gene-editing workflows are supporting demand for CRISPR kits & enzymes, libraries, and specialized services across the market.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 3.19 Billion
Current Market Size (2026): USD 3.48 Billion
Forecast Market Size (2031): USD 6.12 Billion
CAGR (2026–2031): 12.0% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest share of the CRISPR market, at 49.7% in 2025.
Offering Leader: Products accounted for the largest share of the CRISPR market, at 70.7% in 2025.
Application Leader: Drug discovery & development accounted for the largest share of the CRISPR market in 2025.
Product Type Leader: CRISPR kits & enzymes accounted for the largest share of the CRISPR product market in 2025. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
North America's growth is driven by strong biopharmaceutical and biotechnology R&D activity, advanced life sciences research infrastructure, high investment in gene editing and therapeutic development, and the presence of leading market players supporting the adoption of CRISPR products and services. The recurring use of CRISPR kits, enzymes, libraries, guide RNAs, and other products across gene editing, functional genomics, screening, and drug discovery workflows supports product segment growth. CRISPR is increasingly used for target identification and validation, functional genomics, disease modeling, cell engineering, and the development of novel therapeutic candidates.
Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Agilent Technologies, Inc. (US) were identified as some of the star players in the CRISPR market, given their strong market share and product footprint.
Creative Biogene (US), Demeetra AgBio (US), and Fujian SunyBiotech Co., Ltd. (China), among others, have distinguished themselves as startups and SMEs by securing strong footholds in specialized niches, underscoring their potential as emerging market leaders.
The CRISPR market is growing due to the increasing adoption of advanced gene-editing technologies, a rising focus on CRISPR-based therapeutics and precision medicine, expanding use of CRISPR in drug discovery and functional genomics, and ongoing advances in CRISPR-Cas systems, gRNA design, and high-throughput CRISPR screening.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The CRISPR market is shifting from conventional CRISPR-Cas9 nuclease systems toward more precise and versatile gene-editing platforms with improved efficiency, specificity, and safety. Adoption of high-fidelity and engineered Cas nucleases, base editing, prime editing, CRISPRa/CRISPRi, and epigenome-editing systems is increasing, enabling more targeted genome modification with reduced off-target effects. Additionally, advances in viral and non-viral delivery systems, automated CRISPR design and workflow platforms, and scalable GMP-compatible processes are supporting broader use across pharmaceutical and biotechnology companies, academic institutes, CROs, and CDMOs. Growing demand for faster target validation, efficient in vivo and ex vivo delivery, and scalable therapeutic development is further accelerating market growth. These advances are supporting the development of safer gene-editing therapies, faster targeted drug discovery, and potentially more durable therapeutic outcomes.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Growing demand for CRISPR-based gene therapies
-
Advancements in CRISPR technology
Level
-
Technical challenges associated with CRISPR technology
Level
-
Development of new vaccines and treatments for genetic diseases
-
Expanding industrial and agricultural applications of CRISPR
Level
-
Regulatory hurdles for CRISPR advancements
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing demand for CRISPR-based gene therapies
The growing development of CRISPR-based gene therapies is driving demand for gene-editing products and services. Expanding therapeutic pipelines for genetic disorders, cancer, and other diseases are increasing the use of CRISPR tools across discovery and clinical development. Advances in ex vivo and in vivo editing are further supporting market growth.
Restraint: Technical challenges associated with CRISPR technology
Technical limitations such as off-target effects, variable editing efficiency, unintended genomic changes, and delivery challenges can restrict CRISPR adoption. Achieving precise delivery to target cells and tissues remains particularly challenging for in vivo applications. These issues can increase development costs and require extensive safety validation.
Opportunity: Development of new vaccines and treatments for genetic diseases
CRISPR offers significant opportunities for developing treatments that directly target disease-causing genetic alterations. Advances in base editing, prime editing, and engineered Cas systems are expanding the range of diseases that may be addressable. Growing research across genetic disorders, oncology, and infectious diseases is expected to create new opportunities for CRISPR products and services.
Challenge: Regulatory hurdles for CRISPR advancements
CRISPR-based therapies face stringent regulatory requirements related to safety, off-target effects, long-term outcomes, and manufacturing consistency. Developers must demonstrate reliable editing performance and robust quality control before commercialization. Evolving requirements for newer gene-editing approaches may also increase development complexity and approval timelines.
CRISPR MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
CRISPR gene editing and large-scale CRISPR screening are used across functional genomics and drug discovery to identify and validate disease targets, develop disease models, and investigate drug-resistance mechanisms, including in oncology. | Faster target identification and validation | Improved disease models | Supports discovery of new therapeutic targets |
 |
Genome editing, including CRISPR-enabled approaches, is being applied in agricultural R&D to develop improved crop traits. Bayer highlights applications involving yield, crop quality, disease resistance, resilience, and plant architecture. | Faster development of desired crop traits | Improved resilience and disease resistance | Supports crop productivity and quality |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The CRISPR market ecosystem comprises raw material providers, instrument manufacturers, service providers, end users, and regulatory authorities. Raw material providers, including Merck, Synthego, GenScript, and Danaher, support the market by supplying critical inputs such as Cas enzymes, guide RNAs, nucleic acids, reagents, and other components used in CRISPR workflows. Instrument manufacturers such as Bio-Rad Laboratories, 10x Genomics, Thermo Fisher Scientific, and Illumina provide platforms that support gene editing, single-cell analysis, sequencing, and downstream characterization. Service providers, including Thermo Fisher Scientific, Merck, Caribou Biosciences, and Cellecta, offer CRISPR screening, gRNA design, cell line development, editing, and validation services. End users, including Amgen, Novartis, Merck, and academic research institutes, utilize CRISPR technologies for drug discovery, functional genomics, target validation, therapeutic development, and other research applications. Regulatory authorities such as the US FDA, MHRA, OLAW, ANVISA, and Health Canada establish requirements related to safety, quality, research oversight, and clinical development, particularly for CRISPR-based therapeutic applications.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
CRISPR Market, By Application
In 2025, the drug discovery & development segment dominated the CRISPR market, supported by the growing use of gene editing for target identification, target validation, functional genomics, disease modeling, and therapeutic development. Pharmaceutical and biotechnology companies increasingly use CRISPR-based workflows to investigate gene function, identify disease-associated pathways, and develop engineered cellular models. Growing investment in gene-editing therapeutics and increasing adoption of high-throughput CRISPR screening further strengthen demand for CRISPR technologies in drug discovery and development.
CRISPR Market, By Service
In 2025, the gRNA synthesis & cell line development segment dominated the CRISPR services market. This leadership is supported by the critical role of guide RNA design and synthesis in enabling efficient, specific gene editing, along with growing demand for customized CRISPR-edited cell lines. These services are widely used for gene knockout and knock-in studies, target validation, functional genomics, disease modeling, and drug discovery. Increasing outsourcing of specialized gene-editing workflows is further supporting demand for gRNA synthesis and cell line development services.
CRISPR Services Market, By End User
In 2025, pharmaceutical & biotechnology companies dominated the CRISPR services market due to their strong focus on drug discovery, target validation, functional genomics, and gene-editing therapeutics. These companies use external CRISPR services for gRNA design and synthesis, customized cell line development, screening, editing optimization, and validation. Growing therapeutic pipelines and the need for specialized gene-editing expertise are encouraging outsourcing to CRISPR service providers, supporting demand across this end-user segment.
CRISPR MARKET: COMPANY EVALUATION MATRIX
In the CRISPR market company evaluation matrix, Thermo Fisher Scientific Inc. is positioned as a star player due to its strong presence across CRISPR gene-editing products, research tools, and supporting workflows. The company offers a broad portfolio of CRISPR-Cas9 products, guide RNA solutions, gene-editing reagents, cell engineering tools, and related analytical technologies used across drug discovery, functional genomics, and therapeutic research. Its global reach, extensive product portfolio, strong customer base, and integrated capabilities across gene editing and life sciences research strengthen its competitive position. New England Biolabs is considered an emerging leader in the CRISPR market. The company is strengthening its position through a growing portfolio of CRISPR-related enzymes and genome-editing reagents, including Cas nucleases and supporting molecular biology products. Its strong expertise in enzyme development, focus on high-quality research reagents, and continued expansion of products supporting advanced genome-editing workflows are increasing its relevance across academic, biotechnology, and pharmaceutical research applications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Agilent Technologies, Inc. (US)
- GenScript (US)
- Revvity (US)
- Lonza (Switzerland)
- Danaher Corporation (US)
- Takara Bio Inc. (Japan)
- Creative Biogene (US)
- FUJIAN SUNYBIOTECH CO., LTD. (China)
- EditCo (US)
- Caribou Biosciences, Inc. (US)
- Demeetra AgBio (US)
- OriGene Technologies, Inc. (US)
- Cellecta, Inc. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 3.19 Billion |
| Market Size in 2026 (Value) | USD 3.48 Billion |
| Market Forecast in 2031 (Value) | USD 6.12 Billion |
| Growth Rate | 12.0% |
| Years Considered | 2023-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: CRISPR MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Rest of Europe Breakdown | Country-level market sizing and growth forecasts (Switzerland, Sweden, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia) | Provides granular country-level insights, enabling clients to prioritize high-growth markets |
| Company Evaluation |
|
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions |
RECENT DEVELOPMENTS
- September 2025 : Revvity and Profluent entered into a strategic collaboration combining Revvity's Pin-point base editing platform with Profluent's AI-engineered proteins to create AI-enhanced adenine deaminase base-editing systems. The collaboration also builds on integrating Profluent's OpenCRISPR nuclease with the Pin-point platform, expanding access to customizable next-generation gene-editing systems.
- July 2025 : Merck KGaA launched PURedit Cas9 Cytosine Base Editors, a CRISPR-Cas9 RNP-based editing solution that enables precise C-to-T substitutions without inducing double-stranded DNA breaks.
- July 2025 : Lonza launched the next-generation 4D-Nucleofector LV Unit PRO, a large-scale electroporation platform that supports research and GMP manufacturing. The system is optimized for CRISPR-based knock-out, knock-in, and transposition and enables delivery of complex cargos into up to one billion cells per run.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global CRISPR market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with primary research inputs to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the CRISPR market. The secondary sources used for this study include the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to gather key information on major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the CRISPR market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzyme differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out damaged or unwanted DNA, allowing the remaining DNA to be rearranged in a new way.
The report provides a comprehensive analysis of the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.
Key Stakeholders
- Genome editing/Genome engineering product manufacturers
- CRISPR editing/Genome engineering product manufacturers
- Suppliers and distributors of genomic instruments/systems and consumables
- Contract manufacturing organizations
- Pharmaceutical and biotechnology companies
- Diagnostic centers and medical colleges
- Contract research organizations
- Government associations and research institutes
- Regulatory authorities
- Business research firms
Report Objectives
- To define, describe, and forecast the CRISPR market based on offering, product type, product end user, service, service end user, and application
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall CRISPR market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the CRISPR market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the CRISPR market
- To benchmark players within the CRISPR market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe CRISPR market, by country
- Further breakdown of the Rest of Asia Pacific CRISPR market, by country
- Further breakdown of the Rest of Latin America CRISPR market, by country
- Further breakdown of the Rest of Middle East CRISPR market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the CRISPR Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
- US CRISPR Market
- Canada CRISPR Market
- Germany CRISPR Market
- UK CRISPR Market
- France CRISPR Market
- Italy CRISPR Market
- Spain CRISPR Market
- China CRISPR Market
- Japan CRISPR Market
- India CRISPR Market
- Brazil CRISPR Market
- Rest Of Europe CRISPR Market
- Rest Of Asia Pacific CRISPR Market
- Rest Of Latin America CRISPR Market
Growth opportunities and latent adjacency in CRISPR Market